Viewing Study NCT06814327


Ignite Creation Date: 2025-12-25 @ 5:05 AM
Ignite Modification Date: 2025-12-26 @ 4:08 AM
Study NCT ID: NCT06814327
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-28
First Post: 2024-11-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Assessment of Organ Failure Risk Predictions in ICU
Sponsor: ETH Zurich
Organization:

Study Overview

Official Title: Prospective Assessment of Risk Predictions of Organ Failure in the Intensive Care Unit - Comparing Accuracy of Human and AI Risk Predictions
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: AI4ICU-Obs
Brief Summary: During this observational study, the investigators aim to assess the ability of ICU clinicians to predict the risk of impending organ failure and retrospectively compare it to the performance of previously published machine learning models. The central hypothesis of this study is that the treating physician can predict impending organ failure in adult ICU patients with similar accuracy as the best previously publishes machine learning models.
Detailed Description: In this observational study, clinician's (physicians and nurses) assessment of the estimated imminent organ failure risk in an ICU setting are prospectively collected. Circulatory failure is investigated in the primary objective, and respiratory failure, renal failure, and mortality are investigated in secondary objectives. These assessments investigate the predictive performance and influencing factors for clinician prediction. The assessments will be collected in questionnaires and be performed by the clinicians directly involved in the patient treatment and by clinicians who are not actively responsible for the patient treatment. Furthermore, this study aims to benchmark these risk assessments made by healthcare professionals against retrospectively generated AI risk scores for the same patients and timepoints. The AI risk scores will be calculated retrospectively from a set of models from a systematic search of the current literature. The AI models that will be employed for this analysis will be identified as indicated by a systematic review protocol and must satisfy the following two criteria: they do not require any data beyond what is routinely collected during an ICU stay and may be accessed as open source. Such a comparison is vital for the understanding of the relative accuracy and reliability of AI-based predictions in the context of organ failure risk compared to human performance. The data and findings from this study are anticipated to provide evidence for the clinical utility of AI-based risk scores and pave the way for future research into the optimization of AI systems for healthcare applications.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: